Need professional-grade analysis? Visit stockanalysis.com
$18.33B
N/A
N/A
N/A
Revolution Medicines Inc (RVMD) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $148.90, up 0.18% from the previous close.
Over the past year, RVMD has traded between a low of $34.70 and a high of $152.54. The stock has gained 297.7% over this period. It is currently 329.1% above its 52-week low.
Revolution Medicines Inc has a market capitalization of $18.33B.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Side-by-side comparison against top Healthcare peers.